Recent Updates
Recently added Catalysts

STX-1150

Phase 1

Elevated LDL-C and High Cholesterol | Small molecule | Metabolic |Scribe Therapeutics Inc.|Trials Updated: Sep 21, 2026

STX-1150 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Feb 2026

STX-1150 target and mechanism

Molecular targetPCSK9
Target classGene
ModalitySmall molecule

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMC
Total Trials1
Total Enrollment64

FDA Designations

No designations recorded

STX-1150 clinical trials

STX-1150 · 1 trial · 1 indication

Phase 1 1
NCT07428473A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)Elevated LDL-C and High Cholesterol
RECRUITING64 Analytics
PHASE1RECRUITING
A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
Elevated LDL-C and High Cholesterol
NCT0742847364
Unlock trial analytics

Study Endpoints

Primary Endpoints

Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs)
Up to Week 52 from administration of STX-1150
Incidence and Severity of Serious Adverse Events (SAEs)
Up to Week 52 from administration of STX-1150
Incidence and Severity of Adverse Events of Special Interest (AESI)
Up to Week 52 from administration of STX-1150

Secondary Endpoints

Incidence of dose-limiting toxicities (DLTs)
Within 14 days from administration of STX-1150
Percent Change from Baseline in Plasma PCSK9 Concentration
Up to Week 52
Percent Change from Baseline in LDL-C
Up to 52 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Arm 1EXPERIMENTALPart 1: An open-label, single ascending dose will serve to identify the Dose-Limiting Toxicities (DLTs) and Optimal Biological Dose (OBD) of STX-1150. Part 2: Following Part 1, an open-label, single or multi-dose expansion of the OBD cohort will be conducted to further characterize the effect of STX-1150 and obtain additional safety data at the OBD.

Interventions

NameTypeDescription
STX-1150DRUGDrug: STX-1150 is an investigational product designed to epigenetically silence the PCSK9 gene. Epigenome modulation offers a way to silence genes without changing their underlying DNA sequence.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 70 Years
SexALL
Healthy VolunteersNo
Study Sites3

Inclusion Criteria: * Elevated serum LDL-C with or without LDL-C lowering medication * Willing and able to give informed consent before initiation of any study-related procedures and willing to comply with all required study procedures Exclusion Criteria: * Patients with history of an ASCVD event...

Countries:AustraliaNew Zealand
Unlock Eligibility Criteria

Other drugs targeting PCSK9

Evolocumab AMGN· PHASE3 Evolocumab AMD AMGN· PHASE3 Evolocumab Pre-filled Syringe AMGN· PHASE3 ARO-DIMERPA ARWR· PHASE1 AZD0780 AZN· PHASE3 MK-0616 MRK· PHASE1 Inclisiran NVS· PHASE3 Bococizumab PFE· PHASE3 bococizumab PFS:Pfizer PFE· PHASE1 PF-04950615 PFE· PHASE2 Alirocumab REGN· PHASE3 REGN727 REGN· PHASE1

Explore more on BiopharmaWatch

Scribe Therapeutics Inc. (SCTX)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with SCompanies A to ZEvery biotech and pharma company we track